[Therapy of oculomotor muscle paralysis].
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D006145:Guanethidine / Q000627:therapeutic use; D006801:Humans; D009157:Myasthenia Gravis / Q000150:complications; D009220:Myositis / Q000150:complications; D009224:Myotonia Congenita / Q000150:complications; D009223:Myotonic Dystrophy / Q000150:complications; D009388:Neostigmine / Q000627:therapeutic use; D009883:Ophthalmic Solutions; D009886:Ophthalmoplegia / Q000188:drug therapy* / Q000209:etiology; D011239:Prednisolone
D000893:Anti-Inflammatory Agents; D009883:Ophthalmic Solutions; D009388:Neostigmine; D011239:Prednisolone; D006145:Guanethidine
Therapie der Augenmuskellähmungen.